EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia

Holm Schneider, Smail Hadj-Rabia, Florian Faschingbauer, Christine Bodemer, Dorothy K Grange, Mary E Norton, Riccardo Cavalli, Gianluca Tadini, Holger Stepan, Angus Clarke iD, Encarna Guillén-Navarro, Sigrun Maier-Wohlfart und 2 weitere

Genes · 2023

DOI: 10.3390/genes14010153 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Genes, 2023. Verfasst von Holm Schneider und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Ectodermal Dysplasias and Department of Pediatrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 …. Hauptthemen laut MEDLINE: Ectodermal Dysplasia 1, Anhidrotic, Ectodermal Dysplasia. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry for Education and Research (BMBF), EspeRare Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a rare genetic disorder characte-rised by abnormal development of the skin and its appendages, such as hair and sweat glands, the teeth, and mucous glands of the airways, resulting in serious, sometimes life-threatening complications like hyperthermia or recurrent respiratory infections. It is caused by pathogenic variants of the ectodysplasin A gene (EDA). Most affected males are hemizygous for EDA null mutations that lead to the absence or inactivity of the signalling protein ectodysplasin A1 (EDA1) and, thus, to the full-blown phenotype with inability to perspire and few if any teeth. There are currently no long-term treatment options for XLHED. ER004 represents a first-in-class protein replacement molecule designed for specific, high-affinity binding to the endogenous EDA1 receptor (EDAR). Its proposed mechanism of action is the replacement of missing EDA1 in yet unborn patients with XLHED. Once bound to EDAR, ER004 activates the EDA/NFκB signalling pathway, which triggers the transcription of genes involved in the normal development of multiple tissues. Following preclinical studies, named-patient use cases demonstrated significant potential of ER004 in affected males treated in utero during the late second and third trimesters of pregnancy. In order to confirm these results, we started the EDELIFE trial, a prospective, open-label, genotype-match controlled, multicentre clinical study to investigate the efficacy and safety of intra-amniotic ER004 administration as a prenatal treatment for male subjects with XLHED. This article summarises the rationale, the study protocol, ethical issues of the trial, and potential pitfalls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ectodermal Dysplasia 1, AnhidroticEctodermal DysplasiaFemalePregnancyMaleHumansProspective StudiesEctodysplasinsSkinClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

anhidrosisclinical trialectodermal dysplasiaectodysplasin Afetal therapyprotein replacementsweat glands

Substanzen

Ectodysplasins

Autor:innen und Institutionen

  • Center for Ectodermal Dysplasias and Department of Pediatrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • Department of Dermatology, Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hospitals of Paris, University of Paris-Cité, 75743 Paris,…
  • Department of Obstetrics and Gynecology, University Hospital Erlangen, 91054 Erlangen, Germany.
  • Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University, St. Louis, MO 63110, USA.
  • Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA 94143, USA.
  • Pediatric Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, 20122 Milan, Italy.

ORCID-Profile: Angus Clarke, Athmane Bouroubi, Florence Porte

Förderung

  • German Federal Ministry for Education and Research (BMBF)
  • EspeRare Foundation

Zitieren

APA

Schneider, H., Hadj-Rabia, S., Faschingbauer, F., Bodemer, C., Grange, D. K., Norton, M. E., Cavalli, R., Tadini, G., Stepan, H., Clarke, A., Guillén-Navarro, E., Maier-Wohlfart, S., Bouroubi, A., & Porte, F. (2023). Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes. https://doi.org/10.3390/genes14010153

Vancouver

Schneider H, Hadj-Rabia S, Faschingbauer F, Bodemer C, Grange DK, Norton ME, et al. Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes. 2023. doi:10.3390/genes14010153

BibTeX
@article{Schneider2023,
  author = {Schneider, Holm and Hadj-Rabia, Smail and Faschingbauer, Florian and Bodemer, Christine and Grange, Dorothy K and Norton, Mary E and Cavalli, Riccardo and Tadini, Gianluca and Stepan, Holger and Clarke, Angus and Guillén-Navarro, Encarna and Maier-Wohlfart, Sigrun and Bouroubi, Athmane and Porte, Florence},
  title = {Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia},
  journal = {Genes},
  year = {2023},
  doi = {10.3390/genes14010153}
}
Kostenlos starten →